22 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2035. from the record
Of the 11 now held by other companies, 11 name Patheon Softgels Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2035
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2035 · High confidence
Also notable
Ends Jul 2038 · High confidence
Also notable
Ends Feb 2035 · High confidence
Controlled Release Fumarate Esters
US 9,326,965
The most cited patent in this portfolio, cited by 51 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Anti-Overingestion Abuse Deterrent Compositions
US 10,335,375
A family of 9 related applications built on the 2019 grant. Protection runs to 2038.
Fumarate Ester Dosage Forms with Enhanced Gastrointestinal Tolerability
US 11,903,918
Granted 2024. Too new for citation comparison; protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Aug 2033 · High confidence
Cited by 45 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
now held by Patheon Softgels Inc.
Also notable
Ends Nov 2030 · High confidence
The most cited patent in this portfolio, cited by 71 later US patents, top 10% of utility patents granted in 2014 in our data. Protection runs to 2030.
now held by Patheon Softgels Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Anti-Overingestion Abuse Deterrent Compositions (US 10,335,375) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Fumarate Ester Dosage Forms with Enhanced Gastrointestinal Tolerability (US 11,903,918) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 2 fees due Nov 3, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Controlled Release Fumarate Esters | 20 in force | to Feb 2035 |
| Anti-Overingestion Abuse Deterrent Compositions | 1 in force | to Jul 2038 |
| Fumarate Ester Dosage Forms with Enhanced Gastrointestinal Tolerability | 1 in force | to Feb 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,326,947 | Controlled Release Fumarate Esters In force · High confidence | In force | High confidence | |
| US 9,326,965 | Controlled Release Fumarate Esters In force · High confidence | In force | High confidence | |
| US 9,511,043 | Fumarate Ester Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,517,209 | Fumarate Ester Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,566,259 | Fumarate Ester Dosage Forms In force · High confidence | In force | High confidence | |
| US 9,636,318 | Fumarate Ester Dosage Forms In force · High confidence | In force | High confidence | |
| US 9,636,319 | Fumarate Ester Dosage Forms In force · High confidence | In force | High confidence | |
| US 9,814,691 | Fumarate Ester Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,814,692 | Fumarate Ester Dosage Forms In force · High confidence | In force | High confidence | |
| US 9,820,960 | Fumarate Ester Pharmaceutical Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 22: 11 patents in force now held by others · 25 patents ended · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.